Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC: Herpes Zoster Vaccine Schedules in MS and NMOSD Patients on Anti-CD20 Therapy
NCT07818356Phase 4Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in herpes zoster (HZ) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Humoral vaccine response rate for IgG anti-VZV gE response at 7 months. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07818356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818356.